Update on Follicular Lymphoma: Contemporary Treatment Strategies and Optimal Sequencing

Update on Follicular Lymphoma: Contemporary Treatment Strategies and Optimal Sequencing
Program Summary

While much progress has been made over the last decade in the treatment of follicular lymphoma, it is important not to lose sight of the heterogeneity of this disease.  There still remains an important unmet need for patients with intermediate and high-risk disease. Unfortunately, many of these patients develop recurrent and rapidly progressing disease. Furthermore, many established standard approaches cause significant early toxicity (nausea, vomiting, alopecia, neutropenia, infection, neuropathy) and late toxicity (cardiomyopathy, neuropathy).



This live interactive program will focus on current patient management practices in follicular lymphoma, a review of FDA approved agents, current clinical trials and new prognostic information.


The current clinical application of radioimmunotherapy (RIT), barriers to use, and how it fits into the treatment algorithm will also be discussed. As we look to the future and consider options for effectively treating follicular lymphoma patients who are refractory to both chemotherapy and rituximab, there are compelling data that RIT can play an important role in both chemotherapy- and rituximab refractory disease, leading to high response rates with durable remissions.  Patient outcomes may be positively affected from a re-examination of the treating community to consider a better-defined integration of this approach into the treatment algorithm.  

Educational Objectives:

  1. Summarize the incidence and patient demographics of indolent B-cell NHL, including prognostic factors that aid in accurate diagnosis and guide treatment decisions
  2. Assess options for first-line and subsequent lines of therapy for indolent B-cell NHL and determine the role of radioimmunotherapy
  3. Describe the demonstrated efficacy and safety of approved agents for primary, relapsed, and refractory follicular lymphoma
  4. Formulate treatment strategies for relapsed and refractory indolent B-cell NHL using currently available options in order to optimize outcomes for individual patients.
  5. Identify the mechanisms of resistance of current antibody therapies and the existing treatment options
  6. Recall potential barriers of use of radioimmunotherapy in the community practice setting

Physician Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship of Medical Education Resources (MER) and PleXus Communications. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation:

Medical Education Resources designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nursing Accreditation:

Medical Education Resources is an approved provider of continuing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 1.0 contact hours of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.

Disclosures of Conflicts of Interest:

It is the policy of Medical Education Resources (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to contrl the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported or used in CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

Fee Information:

There is no fee for this educational activity.

Speaker List:

Thomas Witzig, MD  (Chair)
Mayo Clinic, Division of Hematology
Rochester, MN

Leo Gordon, MD
Feinberg School of Medicine, Northwestern University
Robert H. Lurie Comprehensive Cancer Center

Stephanie Gregory, MD
Rush University Medical Center

John Pagel, MD
Swedish Medical Center

Jeffrey Matous, MD
Colorado Blood Cancer Institute


John Leonard, MD
Weill Cornell Medical College
Center for Lymphoma and Myeloma

Mitchell Smith, MD, PhD
Cleveland Clinic-Taussig Cancer Institute, Department of Hematology & Medical Oncology



Please fill in this form to request a hospital meeting.

Your Contact Information

Meeting Specifics

 
This activity has been made possible through an unrestricted educational grant from Spectrum Pharmaceuticals.

Categories: Hospital Events

Social Buttons